<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">Inflammatory bowel diseases</z:e> (IBDs; both <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> [UC] and Crohn's <z:hpo ids='HP_0002583'>colitis</z:hpo> [CC]) are well-established predisposing pathological conditions for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) development </plain></SENT>
<SENT sid="1" pm="."><plain>In IBDs, both the endoscopy and the histology assessment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> precursors (i.e., <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, also defined as intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo>) are associated with low interobserver consistency, and no reliable <z:mpath ids='MPATH_589'>dysplasia</z:mpath>-specific biomarker is available </plain></SENT>
<SENT sid="2" pm="."><plain>The programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> 4 (PDCD4) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene is involved in <z:hpo ids='HP_0003745'>sporadic</z:hpo> colorectal <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e>, but scanty information is available on its involvement in IBD-associated colorectal <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred twenty tissue samples representative of active and inactive IBD and of flat <z:mpath ids='MPATH_589'>dysplasia</z:mpath> were obtained from 30 cases of UC and 30 of CC who undergone colectomy </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty additional biopsy samples obtained from patients with <z:e sem="disease" ids="C0022104" disease_type="Disease or Syndrome" abbrv="IBS">irritable bowel syndrome</z:e> acted as <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="5" pm="."><plain>PDCD4 expression was assessed by immunohistochemistry; the expression of miR-21 (a major PDCD4 regulator) was investigated by quantitative real-time PCR and in situ hybridization in different series of a hundred samples </plain></SENT>
<SENT sid="6" pm="."><plain>Tissue specimens from both controls and inactive IBD consistently featured strong PDCD4 nuclear immunostain; conversely, lower PDCD4 nuclear expression was featured by both active IBD and IBD-associated dysplastic lesions </plain></SENT>
<SENT sid="7" pm="."><plain>Significant PDCD4 down-regulation distinguished IBD-associated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (p &lt; 0.001) versus active IBD </plain></SENT>
<SENT sid="8" pm="."><plain>In both active IBD and <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, PDCD4 down-regulation was significantly associated with miR-21 up-regulation </plain></SENT>
<SENT sid="9" pm="."><plain>PDCD4 nuclear down-regulation (which parallels miR-21 up-regulation) is involved in the molecular pathway of IBD-associated <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>PDCD4 nuclear expression may be usefully applied as ancillary maker in the histological assessment of IBD-associated dysplastic lesions </plain></SENT>
</text></document>